Marianne Guenot is a Science Reporter at Business Insider. She specializes in areas such as artificial intelligence, medicine, healthcare, and natural sciences, covering the intersection of technology and health. Marianne's work has been featured in notable outlets including Business Insider Australia, Yahoo News, and Live Science.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Marianne Guenot's coverage spans scientific, cultural & societal, and entertainment news. She frequently cites data and provides expert commentary on evolving stories within the scientific realm. Pitches to Marianne should emphasize credible sources with expertise in areas such as natural disasters, evolution, space exploration, climate change, ancient discoveries, astronomy, biology; particularly those that involve recent data or unfolding events.
Given her broad coverage of international topics without a specific geographic focus mentioned suggests she is open to insights from various regions around the world.
This information evolves through artificial intelligence and human feedback. Improve this profile .
When clinical trials are suddenly halted by US funding cuts, there are repercussions for investigators and patients, and they do not stop at borders.
By: Marianne Guenot
Trace amounts of antiseptic chemicals in hospital rooms may be driving tolerance and resistance in bacteria, a study finds.
By: Marianne Guenot
Engineers have found a way to fine-tune tiny artificial neurons to fire like real brain cells.
By: Marianne Guenot
Scientists found that blocking a protein best known for its role in asthma enhances cancer immunotherapy in preclinical models.
The European Federation for Science Journalism (EFSJ) invites submissions for the 2026 European Science Journalist of the Year Award.
By: Marianne Guenot
Red-light therapy is a firmly established internet trend. But this time, there’s actually something to it.
By: Marianne Guenot
Researchers report that younger adults with older‑than‑expected biological ages are more likely to develop early‑onset lung, gastrointestinal and uterine cancers, but more research is needed.
By: Marianne Guenot
SpudCell is a new cell-like platform that can feed, grow and divide like a normal cell — but it's not yet a perfect re-creation of the real thing.
Once confined to post-market surveillance, real-world evidence is now being used to emulate trials, guide approvals and even run studies in real time, forcing a rethink of what constitutes a clinical trial.
